Investigation of a nonsense mutation located in the complex KIV-2 copy number variation region of apolipoprotein(a) in 10,910 individuals.


Journal

Genome medicine
ISSN: 1756-994X
Titre abrégé: Genome Med
Pays: England
ID NLM: 101475844

Informations de publication

Date de publication:
21 08 2020
Historique:
received: 27 03 2020
accepted: 05 08 2020
entrez: 23 8 2020
pubmed: 23 8 2020
medline: 4 8 2021
Statut: epublish

Résumé

The concentrations of the highly atherogenic lipoprotein(a) [Lp(a)] are mainly genetically determined by the LPA gene locus. However, up to 70% of the coding sequence is located in the complex so-called kringle IV type 2 (KIV-2) copy number variation, a region hardly accessible by common genotyping and sequencing technologies. Despite its size, little is known about genetic variants in this complex region. The R21X variant is a functional variant located in this region, but it has never been analyzed in large cohorts. We typed R21X in 10,910 individuals from three European populations using a newly developed high-throughput allele-specific qPCR assay. R21X allelic location was determined by separating the LPA alleles using pulsed-field gel electrophoresis (PFGE) and typing them separately. Using GWAS data, we identified a proxy SNP located outside of the KIV-2. Linkage disequilibrium was determined both statistically and by long-range haplotyping using PFGE. Worldwide frequencies were determined by reanalyzing the sequencing data of the 1000 Genomes Project with a dedicated pipeline. R21X carriers (frequency 0.016-0.021) showed significantly lower mean Lp(a) concentrations (- 11.7 mg/dL [- 15.5; - 7.82], p = 3.39e-32). The variant is located mostly on medium-sized LPA alleles. In the 1000 Genome data, R21X mostly occurs in Europeans and South Asians, is absent in Africans, and shows varying frequencies in South American populations (0 to 0.022). Of note, the best proxy SNP was another LPA null mutation (rs41272114, D' = 0.958, R We performed the largest epidemiological study on an LPA KIV-2 variant so far, showing that it is possible to assess LPA KIV-2 mutations on a large scale. Surprisingly, in all analyzed populations, R21X was located on the same haplotype as the splice mutation rs41272114, creating "double-null" LPA alleles. Despite being a nonsense variant, the R21X status does not provide additional information beyond the rs41272114 genotype. This has important implications for studies using LPA loss-of-function mutations as genetic instruments and emphasizes the complexity of LPA genetics.

Sections du résumé

BACKGROUND
The concentrations of the highly atherogenic lipoprotein(a) [Lp(a)] are mainly genetically determined by the LPA gene locus. However, up to 70% of the coding sequence is located in the complex so-called kringle IV type 2 (KIV-2) copy number variation, a region hardly accessible by common genotyping and sequencing technologies. Despite its size, little is known about genetic variants in this complex region. The R21X variant is a functional variant located in this region, but it has never been analyzed in large cohorts.
METHODS
We typed R21X in 10,910 individuals from three European populations using a newly developed high-throughput allele-specific qPCR assay. R21X allelic location was determined by separating the LPA alleles using pulsed-field gel electrophoresis (PFGE) and typing them separately. Using GWAS data, we identified a proxy SNP located outside of the KIV-2. Linkage disequilibrium was determined both statistically and by long-range haplotyping using PFGE. Worldwide frequencies were determined by reanalyzing the sequencing data of the 1000 Genomes Project with a dedicated pipeline.
RESULTS
R21X carriers (frequency 0.016-0.021) showed significantly lower mean Lp(a) concentrations (- 11.7 mg/dL [- 15.5; - 7.82], p = 3.39e-32). The variant is located mostly on medium-sized LPA alleles. In the 1000 Genome data, R21X mostly occurs in Europeans and South Asians, is absent in Africans, and shows varying frequencies in South American populations (0 to 0.022). Of note, the best proxy SNP was another LPA null mutation (rs41272114, D' = 0.958, R
CONCLUSIONS
We performed the largest epidemiological study on an LPA KIV-2 variant so far, showing that it is possible to assess LPA KIV-2 mutations on a large scale. Surprisingly, in all analyzed populations, R21X was located on the same haplotype as the splice mutation rs41272114, creating "double-null" LPA alleles. Despite being a nonsense variant, the R21X status does not provide additional information beyond the rs41272114 genotype. This has important implications for studies using LPA loss-of-function mutations as genetic instruments and emphasizes the complexity of LPA genetics.

Identifiants

pubmed: 32825847
doi: 10.1186/s13073-020-00771-0
pii: 10.1186/s13073-020-00771-0
pmc: PMC7442989
doi:

Substances chimiques

Biomarkers 0
Codon, Nonsense 0
RNA Splice Sites 0
Apoprotein(a) EC 3.4.21.-

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

74

Subventions

Organisme : Austrian Science Fund FWF
ID : P 31458
Pays : Austria

Références

Atherosclerosis. 2008 Nov;201(1):138-47
pubmed: 18304554
Eur Heart J. 2017 Jun 14;38(23):1823-1831
pubmed: 28444229
Arterioscler Thromb Vasc Biol. 2014 Sep;34(9):2095-9
pubmed: 24925971
Hum Mutat. 2004 Dec;24(6):474-80
pubmed: 15523644
Hum Mol Genet. 1998 Feb;7(2):257-64
pubmed: 9425232
J Lipid Res. 2019 Jan;60(1):186-199
pubmed: 30413653
Bioinformatics. 2009 Aug 15;25(16):2078-9
pubmed: 19505943
Bioinformatics. 2010 Mar 15;26(6):841-2
pubmed: 20110278
J Hum Genet. 2015 Dec;60(12):755-61
pubmed: 26377243
J Lipid Res. 2016 Jul;57(7):1111-25
pubmed: 26637279
J Am Coll Cardiol. 2010 May 11;55(19):2160-7
pubmed: 20447543
J Intern Med. 2020 May;287(5):569-579
pubmed: 32037598
J Am Coll Cardiol. 2016 Dec 27;68(25):2761-2772
pubmed: 28007139
BMC Bioinformatics. 2008 May 29;9:253
pubmed: 18510760
Nephrol Dial Transplant. 2015 Mar;30(3):441-51
pubmed: 25271006
N Engl J Med. 2013 Feb 7;368(6):503-12
pubmed: 23388002
J Lipid Res. 1995 Apr;36(4):813-22
pubmed: 7542309
J Am Soc Nephrol. 2000 Jan;11(1):105-15
pubmed: 10616846
JAMA Cardiol. 2019 Jun 1;4(6):575-579
pubmed: 31017618
J Clin Invest. 1991 Jun;87(6):2153-61
pubmed: 1645755
Cardiovasc Res. 2014 Jul 1;103(1):28-36
pubmed: 24760552
Eur Heart J. 2010 Dec;31(23):2844-53
pubmed: 20965889
J Intern Med. 2013 Jan;273(1):6-30
pubmed: 22998429
J Mol Diagn. 2016 Jan;18(1):23-31
pubmed: 26596526
Hum Mol Genet. 1999 Oct;8(11):2087-96
pubmed: 10484779
JAMA Cardiol. 2018 Jul 1;3(7):619-627
pubmed: 29926099
PLoS Genet. 2014 Jul 31;10(7):e1004494
pubmed: 25078778
Nat Rev Drug Discov. 2013 Aug;12(8):581-94
pubmed: 23868113
Clin Biochem. 2015 Oct;48(15):999-1002
pubmed: 25523300
J Lipid Res. 2020 Mar;61(3):432-444
pubmed: 31806727
J Clin Invest. 1994 Apr;93(4):1481-92
pubmed: 8163653
Arterioscler Thromb Vasc Biol. 2020 Jan;40(1):255-266
pubmed: 31578080
Nat Commun. 2018 Jul 4;9(1):2606
pubmed: 29973585
Hum Mol Genet. 1997 Jul;6(7):1099-107
pubmed: 9215681
Arterioscler Thromb Vasc Biol. 2018 May;38(5):1230-1241
pubmed: 29567679
Hum Mol Genet. 2015 Apr 15;24(8):2390-400
pubmed: 25575512
Clin Chem. 2008 May;54(5):851-7
pubmed: 18375480
J Med Genet. 2006 Dec;43(12):917-23
pubmed: 16840570
J Clin Invest. 1992 Jul;90(1):52-60
pubmed: 1386087
Arterioscler Thromb. 1992 Oct;12(10):1214-26
pubmed: 1390593
PLoS One. 2015 Mar 30;10(3):e0121582
pubmed: 25822457
Ann Intern Med. 2009 May 5;150(9):604-12
pubmed: 19414839
Circ Res. 2018 Feb 2;122(3):433-443
pubmed: 29212778
J Am Coll Cardiol. 2019 Dec 17;74(24):2982-2994
pubmed: 31865966
Circ Cardiovasc Genet. 2010 Feb;3(1):39-46
pubmed: 20160194
Arterioscler Thromb. 1992 Mar;12(3):302-6
pubmed: 1532126
Cardiovasc Drugs Ther. 2016 Feb;30(1):87-100
pubmed: 26896185
Nature. 2015 Oct 1;526(7571):68-74
pubmed: 26432245
JAMA. 2009 Jun 10;301(22):2331-9
pubmed: 19509380
Hum Genet. 1992 Nov;90(3):220-30
pubmed: 1336760
Eur Heart J. 2017 Aug 21;38(32):2490-2498
pubmed: 28449027
Gesundheitswesen. 2005 Aug;67 Suppl 1:S26-30
pubmed: 16032514
J Lipid Res. 2016 Mar;57(3):340-51
pubmed: 26538546
Nat Genet. 2016 Nov;48(11):1443-1448
pubmed: 27694958
J Lipid Res. 2009 May;50(5):798-806
pubmed: 19124843
JACC Heart Fail. 2016 Jan;4(1):78-87
pubmed: 26656145
N Engl J Med. 2009 Dec 24;361(26):2518-28
pubmed: 20032323
J Lipid Res. 2017 Sep;58(9):1834-1844
pubmed: 28512139
N Engl J Med. 2020 Jan 16;382(3):244-255
pubmed: 31893580
Atherosclerosis. 2015 Oct;242(2):521-8
pubmed: 26302166

Auteurs

Silvia Di Maio (S)

Institute of Genetic Epidemiology, Department of Genetics and Pharmacology, Medical University of Innsbruck, Schöpfstrasse 41, A-6020, Innsbruck, Austria.

Rebecca Grüneis (R)

Institute of Genetic Epidemiology, Department of Genetics and Pharmacology, Medical University of Innsbruck, Schöpfstrasse 41, A-6020, Innsbruck, Austria.

Gertraud Streiter (G)

Institute of Genetic Epidemiology, Department of Genetics and Pharmacology, Medical University of Innsbruck, Schöpfstrasse 41, A-6020, Innsbruck, Austria.

Claudia Lamina (C)

Institute of Genetic Epidemiology, Department of Genetics and Pharmacology, Medical University of Innsbruck, Schöpfstrasse 41, A-6020, Innsbruck, Austria.

Manuel Maglione (M)

Department of Visceral, Transplant and Thoracic Surgery, Medical University of Innsbruck, Innsbruck, Austria.

Sebastian Schoenherr (S)

Institute of Genetic Epidemiology, Department of Genetics and Pharmacology, Medical University of Innsbruck, Schöpfstrasse 41, A-6020, Innsbruck, Austria.

Dietmar Öfner (D)

Department of Visceral, Transplant and Thoracic Surgery, Medical University of Innsbruck, Innsbruck, Austria.

Barbara Thorand (B)

Institute of Epidemiology, Helmholtz Zentrum München - German Research Center for Environmental Health (GmbH), Neuherberg, Germany.

Annette Peters (A)

Institute of Epidemiology, Helmholtz Zentrum München - German Research Center for Environmental Health (GmbH), Neuherberg, Germany.
German Centre for Cardiovascular Research (DZHK), Partner Site Munich Heart Alliance, Munich, Germany.

Kai-Uwe Eckardt (KU)

Department of Nephrology and Hypertension, Friedrich-Alexander Universität Erlangen-Nürnberg, Erlangen, Germany.
Department of Nephrology and Medical Intensive Care, Charité-Universitätsmedizin Berlin, Berlin, Germany.

Anna Köttgen (A)

Institute of Genetic Epidemiology, Faculty of Medicine and Medical Center, University of Freiburg, Freiburg, Germany.

Florian Kronenberg (F)

Institute of Genetic Epidemiology, Department of Genetics and Pharmacology, Medical University of Innsbruck, Schöpfstrasse 41, A-6020, Innsbruck, Austria.

Stefan Coassin (S)

Institute of Genetic Epidemiology, Department of Genetics and Pharmacology, Medical University of Innsbruck, Schöpfstrasse 41, A-6020, Innsbruck, Austria. Stefan.Coassin@i-med.ac.at.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH